368 related articles for article (PubMed ID: 38356197)
1. ESKAPE in China: epidemiology and characteristics of antibiotic resistance.
Luo Q; Lu P; Chen Y; Shen P; Zheng B; Ji J; Ying C; Liu Z; Xiao Y
Emerg Microbes Infect; 2024 Dec; 13(1):2317915. PubMed ID: 38356197
[TBL] [Abstract][Full Text] [Related]
2. ESKAPE pathogens: antimicrobial resistance, epidemiology, clinical impact and therapeutics.
Miller WR; Arias CA
Nat Rev Microbiol; 2024 Jun; ():. PubMed ID: 38831030
[TBL] [Abstract][Full Text] [Related]
3. Antimicrobial Resistance in ESKAPE Pathogens.
De Oliveira DMP; Forde BM; Kidd TJ; Harris PNA; Schembri MA; Beatson SA; Paterson DL; Walker MJ
Clin Microbiol Rev; 2020 Jun; 33(3):. PubMed ID: 32404435
[TBL] [Abstract][Full Text] [Related]
4. Novel antimicrobial agents for combating antibiotic-resistant bacteria.
Chang RYK; Nang SC; Chan HK; Li J
Adv Drug Deliv Rev; 2022 Aug; 187():114378. PubMed ID: 35671882
[TBL] [Abstract][Full Text] [Related]
5. Epidemiology of community origin of major multidrug-resistant ESKAPE uropathogens in a paediatric population in South-East Gabon.
Mouanga-Ndzime Y; Onanga R; Longo-Pendy NM; Bignoumba M; Bisseye C
Antimicrob Resist Infect Control; 2023 May; 12(1):47. PubMed ID: 37173760
[TBL] [Abstract][Full Text] [Related]
6. Clinical relevance of the ESKAPE pathogens.
Pendleton JN; Gorman SP; Gilmore BF
Expert Rev Anti Infect Ther; 2013 Mar; 11(3):297-308. PubMed ID: 23458769
[TBL] [Abstract][Full Text] [Related]
7. A Whole-Cell Screen Identifies Small Bioactives That Synergize with Polymyxin and Exhibit Antimicrobial Activities against Multidrug-Resistant Bacteria.
Zimmerman SM; Lafontaine AJ; Herrera CM; Mclean AB; Trent MS
Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31844003
[TBL] [Abstract][Full Text] [Related]
8. Risk factors and outcomes of bacteremia caused by drug-resistant ESKAPE pathogens in solid-organ transplant recipients.
Bodro M; Sabé N; Tubau F; Lladó L; Baliellas C; Roca J; Cruzado JM; Carratalà J
Transplantation; 2013 Nov; 96(9):843-9. PubMed ID: 23883973
[TBL] [Abstract][Full Text] [Related]
9. Prevalence of ESKAPE pathogens in the environment: Antibiotic resistance status, community-acquired infection and risk to human health.
Denissen J; Reyneke B; Waso-Reyneke M; Havenga B; Barnard T; Khan S; Khan W
Int J Hyg Environ Health; 2022 Jul; 244():114006. PubMed ID: 35841823
[TBL] [Abstract][Full Text] [Related]
10. Alternatives for the treatment of infections caused by ESKAPE pathogens.
da Rosa TF; Coelho SS; Foletto VS; Bottega A; Serafin MB; Machado CS; Franco LN; de Paula BR; Hörner R
J Clin Pharm Ther; 2020 Aug; 45(4):863-873. PubMed ID: 32339305
[TBL] [Abstract][Full Text] [Related]
11. Patterns of Drug-Resistant Bacteria in a General Hospital, China, 2011-2016.
Mao T; Zhai H; Duan G; Yang H
Pol J Microbiol; 2019; 68(2):225-232. PubMed ID: 31250593
[TBL] [Abstract][Full Text] [Related]
12. CRISPR in Modulating Antibiotic Resistance of ESKAPE Pathogens.
Saha U; Gondi R; Patil A; Saroj SD
Mol Biotechnol; 2023 Jan; 65(1):1-16. PubMed ID: 35939207
[TBL] [Abstract][Full Text] [Related]
13. Eliciting antibiotics active against the ESKAPE pathogens in a collection of actinomycetes isolated from mountain soils.
Zhu H; Swierstra J; Wu C; Girard G; Choi YH; van Wamel W; Sandiford SK; van Wezel GP
Microbiology (Reading); 2014 Aug; 160(Pt 8):1714-1725. PubMed ID: 24794971
[TBL] [Abstract][Full Text] [Related]
14. Characterisation of ESKAPE Pathogens with Special Reference to Multidrug Resistance and Biofilm Production in a Nepalese Hospital.
Pandey R; Mishra SK; Shrestha A
Infect Drug Resist; 2021; 14():2201-2212. PubMed ID: 34163185
[TBL] [Abstract][Full Text] [Related]
15. Antibiotic resistance of ESKAPE group-microorganisms in health institutions from Hermosillo and Ciudad Obregón, Sonora, México.
Álvarez-Ainza ML; Fong-Coronado PA; Ruiz-Bustos E; Castillón-Campaña LG; Quintero-Reyes IE; Duarte-Zambrano LA; Bolado-Martínez E
Front Cell Infect Microbiol; 2024; 14():1348093. PubMed ID: 38516533
[TBL] [Abstract][Full Text] [Related]
16. Detection of ESKAPE Bacterial Pathogens at the Point of Care Using Isothermal DNA-Based Assays in a Portable Degas-Actuated Microfluidic Diagnostic Assay Platform.
Renner LD; Zan J; Hu LI; Martinez M; Resto PJ; Siegel AC; Torres C; Hall SB; Slezak TR; Nguyen TH; Weibel DB
Appl Environ Microbiol; 2017 Feb; 83(4):. PubMed ID: 27986722
[TBL] [Abstract][Full Text] [Related]
17. Genome plasticity as a paradigm of antibiotic resistance spread in ESKAPE pathogens.
Das S; Bombaywala S; Srivastava S; Kapley A; Dhodapkar R; Dafale NA
Environ Sci Pollut Res Int; 2022 Jun; 29(27):40507-40519. PubMed ID: 35349073
[TBL] [Abstract][Full Text] [Related]
18. Whole Genome Sequencing of Extended Spectrum β-lactamase (ESBL)-producing Klebsiella pneumoniae Isolated from Hospitalized Patients in KwaZulu-Natal, South Africa.
Founou RC; Founou LL; Allam M; Ismail A; Essack SY
Sci Rep; 2019 Apr; 9(1):6266. PubMed ID: 31000772
[TBL] [Abstract][Full Text] [Related]
19. In Vitro Emergence of High Persistence upon Periodic Aminoglycoside Challenge in the ESKAPE Pathogens.
Michiels JE; Van den Bergh B; Verstraeten N; Fauvart M; Michiels J
Antimicrob Agents Chemother; 2016 Aug; 60(8):4630-7. PubMed ID: 27185802
[TBL] [Abstract][Full Text] [Related]
20. Economic burden of antibiotic resistance in ESKAPE organisms: a systematic review.
Zhen X; Lundborg CS; Sun X; Hu X; Dong H
Antimicrob Resist Infect Control; 2019; 8():137. PubMed ID: 31417673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
